Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.70 |
| ▸ | GLS | O94925 | 6/20 | 0.58 |
| ▸ | GLS2 | Q9UI32 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | ESRRA | P11474 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1250446 | 1.00 | NR1H4 (0.70) | NR1H4GLSGLS2NPC1RAB9A | |
| SCHEMBL1250448 | 1.00 | NR1H4 (0.70) | NR1H4GLSGLS2NPC1RAB9A | |
| SCHEMBL1579056 | 0.77 | PIM2 (0.49) | NR1H4PIM1PIM2ESRRA | |
| SCHEMBL1579058 | 0.77 | PIM2 (0.49) | NR1H4PIM1PIM2ESRRA | |
| SCHEMBL12281665 | 0.77 | PIM2 (0.49) | NR1H4PIM1PIM2ESRRA | |
| SCHEMBL9704209 | 0.76 | LMNA (0.47) | POLBMAPTLMNAHPGD | |
| SCHEMBL12282863 | 0.76 | PIM2 (0.47) | NR1H4PIM1PIM2ESRRA | |
| SCHEMBL1580220 | 0.76 | PIM2 (0.47) | NR1H4PIM1PIM2ESRRA | |
| SCHEMBL12281465 | 0.76 | PIM2 (0.47) | NR1H4HPGDPIM1PIM2ESRRA | |
| SCHEMBL2426028 | 0.76 | PIM2 (0.47) | NR1H4HPGDPIM1PIM2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | NR1H4 391/4885GLS 1096/4885GLS2 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.